BRTX
BiorestorativeยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BRTX Profile
Biorestorative Therapies, Inc.
A clinical stage company that develops regenerative medicine products and therapies using cell and tissue protocols
40 Marcus Drive, Suite 1, Melville, New York 11747
--
Biorestorative Therapies, Inc. was incorporated in Nevada on June 13, 1997. The company is currently working on a Disc/Spine program with a preliminary research therapeutic product called BRTX-100. In March 2022, a US patent was issued in the Disc/Spine Program. The company submitted an IND application to the U.S. Food and Drug Administration (FDA) for authorization to begin a Phase 2 clinical trial investigating the use of BRTX-100 for chronic low back pain caused by degenerative disc disease. The company has received such authorization from the FDA and has commenced such clinical trials.
